{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:24Z","timestamp":1793136984885,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.rec.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T14:59:26Z","timestamp":1690383566000},"page":"1042-1054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Gene therapy for heart failure and cardiomyopathies"],"prefix":"10.1016","volume":"76","author":[{"given":"Alessia","family":"Argir\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2023.06.009_bib0011","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene Therapy for Human Genetic Disease?.: Proposals for genetic manipulation in humans raise difficult scientific and ethical problems","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0445","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene Transfer into Humans \u2014 Immunotherapy of Patients with Advanced Melanoma Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0450","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T Lymphocyte-Directed Gene Therapy for ADA\u2212 SCID: Initial Trial Results After 4 Years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0455","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/mthe.2000.0213","article-title":"A Tumultuous Year for Gene Therapy","volume":"2","author":"Verma","year":"2000","journal-title":"Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0460","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rec.2023.06.009_bib0465","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ymthe.2006.03.001","article-title":"Genotoxicity of Retroviral Integration In Hematopoietic Cells","volume":"13","author":"Nienhuis","year":"2006","journal-title":"Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0470","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/156652311796150354","article-title":"Immune Responses to AAV in Clinical Trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr Gene Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0475","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0480","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0485","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3835","article-title":"Pioneering gene therapy on brink of approval","volume":"11","author":"Flemming","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.rec.2023.06.009_bib0490","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrd.2017.212","article-title":"Landmark gene therapy poised for US approval","volume":"16","author":"Morrison","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.rec.2023.06.009_bib0495","unstructured":"U.S. Food and Drug Administration. Cellular & Gene Therapy Guidances. 2 June 2023. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/cellular-gene-therapy-guidances. Accessed 6 Mar 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0500","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0505","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41435-021-00136-6","article-title":"Gene therapy avenues and COVID-19 vaccines","volume":"22","author":"Abu Abed","year":"2021","journal-title":"Genes Immun."},{"key":"10.1016\/j.rec.2023.06.009_bib0510","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41573-020-00096-y","article-title":"Gene-editing pipeline takes off","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.rec.2023.06.009_bib0515","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.2119055","article-title":"Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall","volume":"249","author":"Nabel","year":"1990","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0520","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0140-6736(96)03361-2","article-title":"Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb","volume":"348","author":"Isner","year":"1996","journal-title":"Lancet."},{"key":"10.1016\/j.rec.2023.06.009_bib0525","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectoris","volume":"45","author":"Kastrup","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2023.06.009_bib0530","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/mt.2009.70","article-title":"VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN Trial","volume":"17","author":"Stewart","year":"2009","journal-title":"Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0535","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2023.06.009_bib0540","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.rec.2023.06.009_bib0545","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene Therapy for the Heart Lessons Learned and Future Perspectives","volume":"126","author":"Cannat\u00e0","year":"2020","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2023.06.009_bib0550","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0555","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/gt.2008.183","article-title":"Progress and Prospects: The design and production of plasmid vectors","volume":"16","author":"Gill","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0560","first-page":"442","article-title":"Adeno-associated virus vector integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Curr Opin Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0565","first-page":"1525","article-title":"Advances in High-capacity Extrachromosomal Vector Technology: Episomal Maintenance","volume":"16","author":"Lufino","year":"2008","journal-title":"Vector Delivery, and Transgene Expression. Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0570","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/jgm.1179","article-title":"Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery","volume":"10","author":"Wooddell","year":"2008","journal-title":"J Gene Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0575","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jgm.178","article-title":"Time course of gene expression after plasmid DNA gene transfer to the liver","volume":"3","author":"Herweijer","year":"2001","journal-title":"J Gene Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0580","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0585","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base transposases and prime","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.rec.2023.06.009_bib0590","first-page":"2375","article-title":"Multiply Attenuated","volume":"107","author":"Fleury","year":"2003","journal-title":"Self-Inactivating Lentiviral Vectors Efficiently Deliver and Express Genes for Extended Periods of Time in Adult Rat Cardiomyocytes In Vivo. Circulation."},{"key":"10.1016\/j.rec.2023.06.009_bib0595","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0600","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rec.2023.06.009_bib0605","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/gt.2012.88","article-title":"Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy","volume":"20","author":"Papayannakos","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0610","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic content and evolution of adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J Gen Virol."},{"key":"10.1016\/j.rec.2023.06.009_bib0615","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0167-5273(02)00554-5","article-title":"Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors","volume":"90","author":"Vassalli","year":"2003","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.rec.2023.06.009_bib0620","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cvr\/cvv205","article-title":"Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation","volume":"108","author":"Rincon","year":"2015","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.rec.2023.06.009_bib0625","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu Rev Genet."},{"key":"10.1016\/j.rec.2023.06.009_bib0630","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.rec.2023.06.009_bib0635","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0640","doi-asserted-by":"crossref","first-page":"eabn4704","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"El Andari","year":"2022","journal-title":"Sci Adv."},{"key":"10.1016\/j.rec.2023.06.009_bib0645","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes."},{"key":"10.1016\/j.rec.2023.06.009_bib0650","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1038\/s41467-021-23546-6","article-title":"Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema","volume":"12","author":"Sz\u0151ke","year":"2021","journal-title":"Nat Commun."},{"key":"10.1016\/j.rec.2023.06.009_bib0655","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.rec.2023.06.009_bib0660","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41467-021-20903-3","article-title":"Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA","volume":"12","author":"Rizvi","year":"2021","journal-title":"Nat Commun."},{"key":"10.1016\/j.rec.2023.06.009_bib0665","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0670","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0675","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science."},{"key":"10.1016\/j.rec.2023.06.009_bib0680","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0685","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort","volume":"30","author":"Perocheau","year":"2019","journal-title":"Hum Gene Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0690","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9\u2013dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.rec.2023.06.009_bib0695","doi-asserted-by":"crossref","first-page":"e120474","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.rec.2023.06.009_bib0700","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0705","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector\u2013Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0710","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr."},{"key":"10.1016\/j.rec.2023.06.009_bib0715","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40265-023-01836-1","article-title":"Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression","volume":"83","author":"Ertl","year":"2023","journal-title":"Drugs."},{"key":"10.1016\/j.rec.2023.06.009_bib0720","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet Med."},{"issue":"Suppl_1","key":"10.1016\/j.rec.2023.06.009_bib0725","doi-asserted-by":"crossref","first-page":"A10727","DOI":"10.1161\/circ.144.suppl_1.10727","article-title":"Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease [Abstract]","volume":"144","author":"Greenberg","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2023.06.009_bib0730","unstructured":"Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022. Businesswire. 30 Sept 2022. Available at: https:\/\/www.businesswire.com\/news\/home\/20220930005139\/en\/%C2%A0Rocket-Pharmaceuticals-Announces-Positive-Updates-from-Phase-1-Clinical-Trial-for-RP-A501-in-Danon-Disease-at-the-Heart-Failure-Society-of-America-HFSA-Annual-Scientific-Meeting-2022. Accessed 15 May 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0735","unstructured":"Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy. Rocket Pharmaceuticals. Available at: https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-acquire-renovacor-extending-leadership\/. Accessed 6 March 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0740","doi-asserted-by":"crossref","first-page":"196","DOI":"10.31083\/j.rcm2306196","article-title":"The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies","volume":"23","author":"Pieroni","year":"2022","journal-title":"Rev Cardiovasc Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0745","unstructured":"AVROBIO. AVROBIO Reprioritizes Pipeline Programs. Available at: https:\/\/investors.avrobio.com\/news-releases\/news-release-details\/avrobio-reprioritizes-pipeline-programs\/. Accessed 23 Jun 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0750","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and Investigational Therapeutics for Fabry Disease","volume":"5","author":"Felis","year":"2020","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.rec.2023.06.009_bib0755","unstructured":"4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1\/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposiumTM. 4D Molecular Therapeutics. 22 Feb 2023. Available at: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4d-molecular-therapeutics-presents-interim-data-4d-310-inglaxa\/. Accessed 6 March 2023."},{"issue":"Suppl 2","key":"10.1016\/j.rec.2023.06.009_bib0760","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene Therapy for Duchenne Muscular Dystrophy. Jaiswal J, Nagaraju K, eds","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J Neuromuscul Dis."},{"key":"10.1016\/j.rec.2023.06.009_bib0765","doi-asserted-by":"crossref","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.rec.2023.06.009_bib0770","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.rec.2023.06.009_bib0775","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022. Available at: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-presents-new-data-its-gene-therapy-and-rna. Accessed 6 May 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0780","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0785","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1089\/hum.2019.363","article-title":"Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy","volume":"31","author":"Salami","year":"2020","journal-title":"Hum Gene Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0790","doi-asserted-by":"crossref","first-page":"903139","DOI":"10.3389\/fgeed.2022.903139","article-title":"Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich's Ataxia","volume":"4","author":"Sivakumar","year":"2022","journal-title":"Front Genome Ed."},{"key":"10.1016\/j.rec.2023.06.009_bib0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","author":"Smith","year":"2023","journal-title":"Mol Ther."},{"key":"10.1016\/j.rec.2023.06.009_bib0800","doi-asserted-by":"crossref","first-page":"e13968","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0805","unstructured":"Gillmore J. AHA 22: Results of the CRISPR-Cas9 First-in-Human Trial. Available at: https:\/\/www.uscjournal.com\/video-index\/aha-22-crispr-crispr-cas9-vivo-gene-editing-patients-transthyretin-amyloidosis. Accessed March 6 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0810","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.rec.2023.06.009_bib0815","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat Commun."},{"key":"10.1016\/j.rec.2023.06.009_bib0820","doi-asserted-by":"crossref","first-page":"e130182","DOI":"10.1172\/jci.insight.130182","article-title":"AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight."},{"key":"10.1016\/j.rec.2023.06.009_bib0825","unstructured":"Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones. GlobeNewswire News Room. 1 Sep 2023. Available at: https:\/\/www.globenewswire.com\/en\/news-release\/2023\/01\/09\/2585026\/0\/en\/Tenaya-Therapeutics-Announces-TN-201-IND-Clearance-and-Anticipated-2023-Milestones.html. Accessed 15 May 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0830","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jacbts.2016.08.008","article-title":"Adeno-Associated Virus Serotype 9\u2013Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts With Left Ventricular Dysfunction Secondary to a Myocardial Infarction","volume":"1","author":"Knezevic","year":"2016","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.rec.2023.06.009_bib0835","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2018.08.2181","article-title":"Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations","volume":"72","author":"Dom\u00ednguez","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2023.06.009_bib0840","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1038\/s41467-021-23272-z","article-title":"Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover","volume":"12","author":"Martin","year":"2021","journal-title":"Nat Commun."},{"key":"10.1016\/j.rec.2023.06.009_bib0845","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamacardio.2018.2541","article-title":"Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals","volume":"3","author":"Myers","year":"2018","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.rec.2023.06.009_bib0850","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jacbts.2022.04.002","article-title":"Cardiac Transduction in Mini-Pigs After Low-Dose Retrograde Coronary Sinus Infusion of AAV9-BAG3","volume":"7","author":"Myers","year":"2022","journal-title":"JACC Basic Transl Sci."},{"issue":"Suppl_1","key":"10.1016\/j.rec.2023.06.009_bib0855","doi-asserted-by":"crossref","DOI":"10.1161\/circ.146.suppl_1.13599","article-title":"Abstract 13599: LX2020, an Adeno Associated Viral-Based Plakophilin 2 Gene Therapy Stabilizes Cardiac Disease Phenotype in a Severe Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"146","author":"Sheikh","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2023.06.009_bib0860","unstructured":"Tenaya Therapeutics, Inc. Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy. Available at: https:\/\/investors.tenayatherapeutics.com\/news-releases\/news-release-details\/tenaya-therapeutics-receives-orphan-drug-designation-us-food-and\/. Accessed 31 March 2023."},{"key":"10.1016\/j.rec.2023.06.009_bib0865","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/cr.2016.101","article-title":"Genome editing with CRISPR\/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome","volume":"26","author":"Xie","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.rec.2023.06.009_bib0870","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/CIRCULATIONAHA.121.055313","article-title":"Restoration Rescue Hutchinson-Gilford Progeria Syndrome","volume":"144","author":"S\u00e1nchez-L\u00f3pez","year":"2021","journal-title":"Circulation."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585723002037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585723002037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:02:50Z","timestamp":1761822170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585723002037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":87,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1885585723002037"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2023.06.009","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for heart failure and cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2023.06.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}